{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:04:24Z","timestamp":1780452264382,"version":"3.54.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lumateperone has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia in adults since 2019, however, there is still a lack of data report on adverse reactions in real-world settings. Conducting data mining on adverse events (AEs) associated with Lumateperone and investigating the risk factors for serious AEs can provide valuable insights for its clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>AE reports in the FDA Adverse Event Reporting System (FAERS) from 2019 Q4 (FDA approval of Lumateperone) to 2024 Q1 were collected and analyzed. Disproportionality in Lumateperone-associated AEs was evaluated using the following parameters: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). Univariate and multivariate logistic regression analyses were conducted to identify the risk factors for Lumateperone-induced severe AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2,644 reports defined Lumateperone as the primary suspected drug was collected, including 739 reports classified as severe AEs and 1905 reports as non-severe AEs. The analysis revealed that 130 preferred terms (PTs) with significant disproportionality were based on the four algorithms, 67 (51.53%) of which were not included in the product labeling, affecting 6 systems and organs. In addition, dizziness (81 cases) was the most reported Lumateperone-associated severe AEs, and tardive dyskinesia showed the strongest signal (ROR = 186.24). Logistic regression analysis indicated that gender, bipolar II disorder, and concomitant drug use are independent risk factors for Lumateperone-associated severe AEs. Specifically, female patients had a 1.811-fold increased risk compared with male patients (OR = 1.811 [1.302, 2.519], <jats:italic>p<\/jats:italic> = 0.000), while patients with bipolar II disorder had a 1.695-fold increased risk compared with patients diagnosed with bipolar disorder (OR = 1.695 [1.320, 2.178], <jats:italic>p<\/jats:italic> = 0.000). Conversely, concomitant use of CYP3A4 inhibitors or drugs metabolized by CYP3A4 was associated with a decreased risk of severe AEs (OR = 0.524 [0.434, 0.633], <jats:italic>P<\/jats:italic> = 0.000).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Collectively, this study provides critical insights into the safety profile of Lumateperone. It highlights the need for cautious use in high-risk populations, such as females and individuals with bipolar II disorder, and emphasizes the importance of monitoring for AEs, including dizziness and tardive dyskinesia. Healthcare also should remain alert to potential AEs not listed in the prescribing information to ensure medical safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1472648","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:40:06Z","timestamp":1727066406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Yanjing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/09540261.2023.2261544","article-title":"Managing drug-induced psychosis","volume":"35","author":"Balda\u00e7ara","year":"2023","journal-title":"Int. Rev. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.mayocp.2017.06.022","article-title":"The diagnosis and management of bipolar I and II disorders: clinical practice update","volume":"92","author":"Bobo","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","volume":"29","author":"Corponi","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.schres.2020.12.006","article-title":"Safety and tolerability of lumateperone 42 mg: an open-label antipsychotic switch study in outpatients with stable schizophrenia","volume":"228","author":"Correll","year":"2021","journal-title":"Schizophr. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/1060028020936597","article-title":"Lumateperone: a novel antipsychotic for schizophrenia","volume":"55","author":"Greenwood","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11920-022-01344-1","article-title":"Lumateperone for the treatment of adults with schizophrenia: a systematic review","volume":"24","author":"Jawad","year":"2022","journal-title":"Curr. Psychiatry Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.3390\/medicina58111584","article-title":"Polypharmacy management of antipsychotics in patients with schizophrenia","volume":"58","author":"Kamei","year":"2022","journal-title":"Med. Kaunas."},{"key":"B14","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.3390\/ijms24119482","article-title":"Towards novel potential molecular targets for antidepressant and antipsychotic pharmacotherapies","volume":"24","author":"Kositsyn","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1283247","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","article-title":"Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database","volume":"354","author":"Lu","year":"2024","journal-title":"J. Affect Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"22m14739","DOI":"10.4088\/JCP.22m14739","article-title":"The efficacy of lumateperone in patients with bipolar depression with mixed features","volume":"84","author":"McIntyre","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1111\/bcp.15777","article-title":"Paroxysmal dystonia and psychotic exacerbations in chronic psychosis: diagnostic dilemmas and preliminary treatment approaches","volume":"89","author":"Mishra","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"711943","DOI":"10.3389\/fgene.2021.711943","article-title":"CYP3A4\u221722 genotyping in clinical practice: ready for implementation?","volume":"12","author":"Mulder","year":"2021","journal-title":"Front. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2020.1795126","article-title":"Up-to-date expert opinion on the safety of recently developed antipsychotics","volume":"19","author":"Orsolini","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.schres.2013.02.010","article-title":"Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score","volume":"146","author":"Pilla Reddy","year":"2013","journal-title":"Schizophr. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1176\/appi.ajp.161.8.1324","article-title":"Gender differences in the prescribing of antipsychotic drugs","volume":"161","author":"Seeman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacol. Berl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/0269881120903466","article-title":"Sex differences in text-mined possible adverse drug events associated with drugs for psychosis","volume":"34","author":"S\u00f8rup","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00406-021-01358-5","article-title":"Detailing the effects of polypharmacy in psychiatry: longitudinal study of 320 patients hospitalized for depression or schizophrenia","volume":"272","author":"Stassen","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1408135","DOI":"10.3389\/fphar.2024.1408135","article-title":"A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","article-title":"A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1472648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:40:08Z","timestamp":1727066408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1472648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":32,"alternative-id":["10.3389\/fphar.2024.1472648"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1472648","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"article-number":"1472648"}}